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Endometrial cancer contains estrogen and progestin receptor proteins. The receptor content
inversely correlates with histologic differentiation. The correlation between receptor content and
histologic subtype and stage of the disease may depend upon the degree of differentiation of the
tumor. The status of the peritoneal cytology and depth of myometrial invasion by tumor do not
correlate with the receptor status. In general, patients with receptor-rich tumors have a better
prognosis than those without receptors and respond favorably to progestin therapy. The level of
the receptor protein in the tumor may also influence survival.
INTRODUCTION
The female reproductive system has been extensively analyzed for the presence of
steroid receptor proteins, both in normal and malignant states [1-8]. In breast cancer,
estrogen and progestin receptor content has been established as an important predictor
of response to therapy and a predictor of survival [9-15]. In the United States,
endometrial cancer is the most common gynecologic malignancy and it has been most
frequently studied for the existence of steroid receptor proteins [16]. Many clinico-
pathologic features of this disease have been shown to be associated with prognosis,
including stage ofthe disease, histologic grade ofthe tumor, histologic subtype, age of
the patient, nuclear grade of the tumor, depth of myometrial invasion by the tumor,
pelvic and/or periaortic nodal status, and status of the peritoneal washings [17-22].
More recently, sex steroid receptor proteins in the tumor have been studied, and the
receptor levels have been correlated with many of these predictive parameters
[6,17,23-36]. Furthermore, the hormone receptor status of the tumor has been
correlated with absolute and disease-free survival [23-30,37] and with response of
recurrent and advanced disease to hormonal therapy and/or cytotoxic chemotherapy
[6,29,34,38-40]. This review ofthe English-language literature from 1980 will outline
these investigations and analyze especially the predictive value of the level of the sex
steroid receptor in the tumor as a prognosticator for survival.
SEX STEROID RECEPTOR PROTEIN ANALYSIS
The usual technique in the clinical literature for assaying the steroid receptor
protein in tumors involves a cytosol analysis for the unoccupied receptor. Briefly, the
tissue obtained either from a uterine curettage or directly from the endometrium after
hysterectomy is dissected into a tumor component and a connective and adipose tissue
component. The tumor specimen is stored at -700C until analysis. The specimen is
then homogenized and centrifuged to produce a soluble cytoplasmic fraction. The
protein in the cytoplasmic fraction and/or the DNA in the particulate fraction are
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quantitated. The total bound steroid ligand levels areobtained byincubating an aliquot
of the cytosol with the appropriate radiolabeled steroid at various temperature and
time considerations in order to reach binding equilibrium. Nonspecific bound steroid
levels are obtained by simultaneously incubating in the presence of 100-fold molar
excess ofnon-radiolabeled competitor. With such a large concentration ofcompetitor,
the radiolabeled steroid is displaced from the receptor binding sites that are present in
a limited number but not from the high-capacity, nonspecific binding sites. The
receptor binding capacity is calculated by subtracting the level of cytosol nonspecific
bound steroid ligand from the total cytosol bound radioligand. The separation of the
free and receptor-bound radioligand is then usually done by one of the following
methods: sucrose density gradient sedimentation, selective adsorption of unbound
steroid on dextran-coated charcoal, adsorption ofthe receptor-steroid complex (e.g., to
hydroxylapatite), or gel filtration. The radioactivity associated with specific binding
and the specific activity of the radiolabeled steroid are used to determine the steroid
receptor levels. The levels of steroid receptor protein are expressed in femtomoles
(10-" moles) of radiolabeled steroid bound per milligram of cytosol protein or per
milligram ofDNA [41]. Becauseofthevarious biochemical methods used, the levelsof
receptor protein reported will differ. Some methods measure the total binding or sites
by "exchange" assays, as opposed to measurement of only unoccupied receptor sites.
Other factors which may affect the level obtained include: single-point determination
of protein binding versus a Scatchard analysis, determination of cytosol fractions
versus total fraction, or inclusion or non-inclusion of reagents in the assay to prevent
the binding ofradioactive ligand to serum binding proteins [42].
In the older literature, the receptor was postulated to be in the cytosol component,
and assays were therefore reported as cytoplasmic steroid receptor analyses. The
current theory regarding the estrogen receptor protein postulates that the unoccupied
estrogen receptor is a nuclear protein bound by low-affinity interactions to nuclear
components. Estrogen, a lipophilic compound, diffuses through thecellular membrane,
the cytoplasm, and the nuclear envelope, where it reacts with the nuclear receptor in
target cells. Next a conformational change in the receptor complex leads to new
physical properties and a high affinity for nuclear components, including chromatin
proteins, the nuclear matrix, and DNA. This change causes an increase in transcrip-
tion of a variety of genes in these target cells. The progestin receptor is thought to be
synthesized in response to the successful interaction of estrogen with its own receptor
protein [43].
Early Observations on Hormonal Therapy
The treatment of endometrial cancer with hormones, in particular with progestins,
was established prior to the biochemical identification of estrogen and progestin
receptors [44]. Several initial reports recognized that many factors influenced the
sensitivity of the endometrial cancer to hormonal manipulation, including the extent
and location of metastatic disease, location of metastases outside the radiation ports,
histologic differentiation, time interval between the initial treatment and recurrence,
the age of the patient at diagnosis, therapeutic modalities prior to hormonal therapy,
the type ofprogestin therapy used, and the length oftreatment [33]. It was only later,
with the identification of the receptor proteins, that a rational basis for these obser-
vations could be developed.
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SamplingProblems
Most clinical studies on the receptor content in endometrial cancer are based on
tissue obtained from curettings at the time of dilatation and curettage. This method
leads to contamination with non-malignant fragments, including glandular and
stromal components. Even in the postmenopausal uterus, the normal endometrium
may have elevated steroid receptor levels. Mortel et al. [31], clearly outlined cell
heterogeneity, tissue heterogeneity, and tumor heterogeneity as the problems which
interfered with receptor determinations when using this technique ofobtaining tissue.
Cell heterogeneity refers to the fact that the endometrium is composed of two major
cell types: glandular epithelium and stroma. Since endometrial cancer arises from the
epithelial cells, the determination of steroid receptor levels should reflect the levels in
these cells and not in those of the stromal component, which may also contain the
receptor proteins. Hence, techniques for separating the glandular elements from the
stroma may be necessary inorder to determine the steroid levels moreaccurately, since
Mortel et al. [31] have shown an increased level of progestin receptor in the isolated
glandular element free of stroma compared to the undissociated tissue. Tissue hetero-
geneity refers to the fact that the curetting may contain not only cancerous glandular
elements, but also normal or hyperplastic endometria. These benign components of
glandular tissue may have high levels ofsteroid receptors, and so even a small fragment
will alter thevalue obtained from the analysis ofthe tissue homogenate. Finally, tumor
heterogeneity refers to the fact that it is not uncommon for a tumor to be composed of
various degrees ofdedifferentiation of the glandular element. Hence, the biochemical
determination on a fragment of cancer will depend on the degree of differentiation in
the sample, which may not reflect the tumor as a whole. As will be noted later, the level
of tumor differentiation correlates with the level of the steroid receptor obtained.
Tsibris et al. have shown that the steroid receptor proteins have an uneven distribution
throughout the endometrial cavity [45]. Soper et al. [46], in a review of422 specimens
submitted for biochemical analysis ofsteroid receptor levels, found that 4.0 percent of
the specimens had no evidence of carcinoma on permanent histologic section. More-
over, an additional 2.5 percent of the specimens contained only focal adenocarcinoma
on permanent histologic sections but had no malignancy in the frozen section
submitted for steroid receptor analysis.
These specimens were obtained by endometrial biopsy or curettage, by hysterecto-
my, or by directed biopsy of metastatic lesions. In a subsequent review by the same
authors [47] of 100 specimens submitted for analysis, histologic components other
than malignantepitheliumaccounted forthemajorityofspecimens in 20 percentofthe
cases, while in only 5 percent of the cases did the specimen contain only malignant
cells. This finding emphasizes that contamination by non-malignant fragments causes
inaccuracy in evaluating endometrial tumors by the biochemical method because it
uses tissue homogenates. Additional technical problems arise with the biochemical
analysis because a prolonged period between obtaining the tissue and processing the
tissue may lead to loss ofreceptor protein.
IMMUNOHISTOCHEMICAL TECHNIQUES
With the problem ofcontamination ofthe specimen by non-malignant components,
the development of newer immunohistochemical techniques to localize the receptor to
the malignant cells has become important. Only a limited number of clinical studies
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have appeared which address this problem in endometrial cancer. Initial studies using
fluorescent-conjugated steroids or anti-steroid hormonal antibodies were unsuccessful
[48,49]. Mutch et al. [50], in 96 specimens obtained at hysterectomy from patients
with stages I to IV endometrial cancer, compared clinical and pathologic associations
of biochemical and immunohistochemical estrogen receptor assays to evaluate the
significance for the estrogen receptor contribution ofthe non-malignant components.
Using the monoclonal antibody H222 gamma, developed against the MCF-7 breast
cancer estrogen receptor by Abbott Laboratories, and amplified by peroxidase/
antiperoxidase stains and a semi-quantitative scoring system incorporating both the
intensity and distribution of the receptor, Mutch and co-workers demonstrated a 91.5
percent sensitivity and a 93.1 percent specificity for the immunohistochemical analysis
compared with the biochemical analysis ofestrogen receptor in the tissues. The cancer
component semi-quantitative score derived from the immunohistochemical method
correlated better with the histologic grade of the tumor than did the biochemical
estrogen receptor determination. Decreasing biochemical estrogen receptor levels
predicted advanced surgical stage (p = 0.0003), as did the total semi-quantitative
coefficient (p = 0.0003) (sum of scores from four histologic components: benign
epithelium, malignant epithelium, stroma, and myometrium). Although immunohisto-
chemical analysis predicted biologic differentiation better than did the biochemical
estrogen receptor analysis, stage correlated better with biochemical estrogen analysis
and total semi-quantitative score than did the cancer component score. This study of
endometrial cancer using immunohistochemical techniques for localization and quan-
tification of the estrogen receptor to the malignant component may permit better
understanding of the biologic behavior than techniques involving whole-tissue homo-
genates. Other studies in animal models for localization ofthe estrogen and progestin
receptors have recently appeared in the literature [51-53].
CLINICOPATHOLOGIC CORRELATIONS
Many studies investigating the relationship between the steroid receptor level and
histologic differentiation of the tumor have shown that the more differentiated
the tumor, the higher the content of both estrogen and progestin receptor protein
[6,23-29]. Ehrlich et al. [6] reported the presence of cytoplasmic estrogen and
progestin receptors in a spectrum of endometria ranging from normal to hyperplastic
and cancerous states. A decreasing concentration ofthe progestin receptor activity was
observed with increasing tumor dedifferentiation. Chambers et al. [23], in an analysis
of 213 postmenopausal women with primary endometrial cancer, showed that the
mean estrogen receptor levels (p= 0.008) and mean progestin receptor levels
(p = 0.0001) were related significantly in an inverse fashion to the histologic grade of
the tumor and that the levels ofthe receptors (p = 0.0001) correlated with each other.
Of77 tumors from patients with stage I and II disease that wereestrogen receptor- and
progestin receptor-rich, 32.4 percent were well-differentiated adenocarcinomas and
15.5 percent were poorly differentiated adenocarcinomas, whereas, of 18 tumors in this
group of patients that were estrogen receptor- and progestin receptor-poor, only 5.5
percent were well-differentiated tumors and 61.1 percent were poorly difflerentiated
tumors. There are, however, reports that do not confirm the relationship between
hormone receptor status and grade ofthe tumor [30,32,33].
Receptor-rich tumors for endometrial cancer are defined arbitrarily with cut-off
levels for positivity of the estrogen receptor ranging from 3 to greater than 100
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fmol/mg of protein and for positivity of the progestin receptor ranging from 5 to
greater than 100 fmol/mg of protein [6,24-30,37]. Thus comparing statements about
the correlations of various clinicopathologic features and receptor status is difficult;
furthermore, different biochemical assays are often employed, so that the level of the
receptor content is also variable. Even with this problem, many statements concerning
hormone receptor levels or status and outcome agree, as will be noted below.
Many authors have noted a correlation between the level or status of estrogen and
progestin receptor and the stage of endometrial cancer [23,24,26,27]. Chambers et al.
[23], in a review of 213 patients with stages I to IV endometrial cancer, showed that
estrogen receptor positivity (>20 fmol/mg of protein) correlated with the stage of
disease. On the other hand, progestin receptor positivity (>7 fmol/mg of protein) was
not associated with stage of disease. Others have not observed this relatinship [30].
The relationship between steroid receptor and histologic subtype has been investi-
gated by many authors, but few have simultaneously controlled for the histologic
differentiation of the tumor. For example, in Chambers et al. [23], the mean estrogen
receptor level for adenocarcinoma was 65.1 fmol/mg of protein compared with 29.0
fmol/mg of protein for the adenosquamous tumors; however, this latter group had
predominantly poorly differentiated tumors. On the other hand, the progestin receptor
levels did not significantly differ with histologic classification. Liao et al. [26], in
analyzing 86 cases of primary endometrial cancer, did not see a relationship between
histologic subtype and hormonal receptor level of the tumor. Creasman et al. [25], in a
study of 168 patients with stages I and II endometrial cancer, found a statistically
significant relationship between progestin receptor status and histologic subtypes;
however, the grade ofthe tumors was not controlled in this observation.
The penetration of the tumor into the myometrium has been demonstrated to be
related to prognosis, but this condition usually correlates with the degree ofdifferentia-
tion of the tumor. The correlation between steroid receptor levels and/or status and
depth of invasion into the myometrium by tumor does not show a consistent trend,
especially if the study controls for tumor differentiation. Chambers et al. [23] showed
that, in patients with early endometrial cancer, there was a statistically significant
association (p = 0.025) between estrogen receptor status and depth of myometrial
invasion; in fact, in stage I and II patients, 68.4 percent ofpatients with no myometrial
invasion had estrogen receptor-rich tumors, whereas only 44.0 percent of the patients
with tumors invading at least 50 percent ofthe myometrium had estrogen-rich tumors.
On further analysis, however, the covariable grade appears to account for this
observation. Analysis of the estrogen receptor level and depth of invasion showed no
correlation. There was no correlation between progestin receptor status and myome-
trial invasion. The mean progestin receptor level for tumor invading less than 50
percent was, however, 180.4 fmol/mg of protein compared with 92.1 fmol/mg of
protein for tumors invading at least 50 percent. Although these values were signifi-
cantly different, both levels represent high content of progestin receptor. Creasman et
al. [25] also showed no relationship between the invasiveness of the tumor into the
myometrium and the hormonal receptor status. Quinn et al. [28], in a study of 155
endometrial carcinomas, carefully analyzed the steroid receptor level and/or status of
the tumors and myometrial invasion, controlling not only for degree of differentiation
but also for histologic subtype. They showed that deep invasion (greater than
two-thirds through the myometrium) was significantly less likely in the estrogen
receptor-positive tumor (p < 0.001) or the progestin receptor-positive tumor
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(p < 0.001) (both .5 fmol/mg of protein). This relationship held true, however, only
for poorly differentiated estrogen receptor-rich tumors if histologic subtypes were
analyzed separately. Furthermore, no poorly differentiated, deeply invasive tumor was
estrogen receptor-rich, and the mean estrogen receptor level (p = 0.01) and mean
progestin receptor level (p < 0.05) were significantly lower in well-differentiated
tumors invading more than one-third of the myometrium than those invading less.
Others have not controlled for the grade of the tumor in investigating the depth of
invasion [27,29].
Geisinger et al. [24], in a series of43 patients with stages I to IV disease, showed a
significant relationship between receptor status (>10 fmol/mg of protein for both
receptors) and vascular space invasion, the majority of the tumors with such invasion
being negative for both receptors, while, in neoplasms lacking such invasion, 81 percent
were estrogen receptor-positive and 91 percent were progestin receptor-positive.
Age and steroid receptor content or status do not correlate, as is noted by several
authors [23,29]. The peritoneal cytology at hysterectomy and hormonal receptorstatus
have no correlation [23,25]. Others have shown no correlation between menstrual
status and mean estrogen or progestin content ofthe tumor [26,29].
SURVIVAL AND STEROID RECEPTORS
Many studies have noted the influence of the steroid receptor content on survival.
Table 1 summarizes the results from the papers discussed. Martin et al. [37] showed a
significantly increased survival time for women with estrogen receptor-positive adeno-
carcinoma compared with negative ones (p < 0.02). Geisinger et al. [24] found that
progestin-positive tumor (p = 0.003) as well as quantitative level of the progestin
receptor (p = 0.012) were significantly related to survival. In dividing the progestin
levels into 0-10 fmol/mg ofprotein, 10-200fmol/mg ofprotein, and >200 fmol/mg of
protein, little difference in survival (deaths from all causes) was found between the
latter two groups, suggesting that simply the presenceofthe progestin receptor protein,
and not the level of content above the cut-off of 10 fmol/mg of protein, gave a better
prognosis for survival. Analyzing deaths due to cancer, the presence or absence of the
estrogen receptor protein and the quantitative levels ofthe estrogen receptor were both
significant variables for survival. Dividing estrogen receptor levels into 0, 1 to 100
fmol/mg of protein, and greater than 100 fmol/mg of protein, three distinct survival
categories were generated. Patients with tumors having no estrogen receptor content
had the worst prognosis; those in the middle group had an intermediate prognosis, and
no patient with greater than 100 fmol/mg protein died secondary to endometrial
cancer.
Creasman et al. [25] showed that estrogen receptor-positive status (p < 0.01),
progestin receptor-positive status (p < 0.001), and combined estrogen receptor- and
progestin receptor-positive status (p < 0.01) had a significantly better disease-free
survival than those with negative receptor status tumors. Furthermore, by multiregres-
sion analysis, estrogen receptor status, progestin receptor status, and combined
estrogen and progestin receptor status wereeach independent predictors ofsurvival. In
further analysis of this finding, progestin receptor status was more significant than
estrogen receptor status in predicting survival. In addition, hormonal receptor status
replaced histologic grade and nuclear grade of the tumor as an independent predictor
ofsurvival.
In 187 patients with stage I and II disease, Chambers et al. [23] showed that the
344HORMONE RECEPTORS AND ENDOMETRIAL CANCER
TABLE 1
Steroid Receptor Status and Survival
No. of
Author Patients Stages ER+ PR+ Comments
Martin et al. [37] 87 I-IV 25 ER+ patients had significantly prolonged
survival.
Geisinger et al. [24] 43 I-IV 210 210 ER+ and/or PR+ patients had signifi-
cantly prolonged survival; presence of
progestin receptor and not level was
important.
Creasman et al. [25] 168 I-II .10-15 .10-15 MultivariateanalysisshowedthatER
and PR status replaced histologic and/
or nuclear grade as predictors ofsur-
vival.
Chambers et al. [23] 187 I-II .20 .7 ER status and/or PR status were inde-
pendent predictors ofsurvival, depend-
ing on cut-offlevels.
ER+, PR+: cut-offlevels for positivity ofreceptor protein expressed in fmol/mg protein
ER+, estrogen receptor-positive
PR+, progestin receptor-positive
patients with estrogen receptor-rich tumors (p = 0.0003) or with progestin receptor-
rich tumors (p = 0.0016) had a significantly increased survival compared with those
having receptor-poor tumors. The receptor protein status was then divided into low,
intermediate, and high ranges for the estrogen receptor content, choosing 0-19
fmol/mg of protein, 20-100 fmol/mg of protein, and greater than 100 fmol/mg of
protein respectively. Three distinct survival curves were generated. Analysis of these
curves demonstrated that the intermediate and high-range curves were not statistically
different, but both were significantly different from the low-range curve. The patients
in the latter two groups had statistically better survival than those in the low-range
group. In a similar fashion, the levels of the progestin receptor content were divided
into three distinct ranges: 0-6 fmol/mg of protein, 7-50 fmol/mg of protein, and
greater than 50 fmol/mg of protein. Analysis showed that the survival curves for the
low and intermediate ranges were not significantly different; however, both were
significantly different from the curve of the high range. The patients in the last group
had statistically better prognosis than those in the other two groups. Using this
information in this population, it appeared that the appropriate cut-offs were 20
fmol/mg ofprotein for the estrogen protein receptor and 50 fmol/mg ofprotein for the
progestin protein receptor. Multivariate analysis showed that of estrogen receptor
level, progestin receptor level, and grade, only grade was a statistically significant
(p = 0.045) predictor of survival. Those with the least differentiated tumors had the
worst prognosis. Further analysis, using estrogen and progestin status and grade,
showed that estrogen receptor status alone was a significant (p = 0.017) predictor of
survival, with the estrogen receptor-positive patients having the best prognosis. This
result held true even if the progestin receptor-positive status was defined at greater
than 50 fmol/mg ofprotein. Using the median values ofthe hormone receptor content
in the tumors as cut-offs, i.e., 31 fmol/mg of protein for the estrogen receptor and 53
fmol/mg of protein for the progestin receptor, further analysis revealed that of
estrogen receptor status, progestin receptor status, and grade, only the progestin
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receptor status was a significant (p = 0.005) predictor of survival. Thus, no unique
cut-offlevel for either the progestin or estrogen receptor appears to exist for predicting
the best survival. In the subgroup ofpatients with stage I and II disease whose tumors
were both estrogen and progestin receptor-negative, the survival at two and five years
was only 51.3 percent and 20.5 percent, respectively. Even in thegroupofpatients with
poorly differentiated adenocarcinoma, the two- and five-year survivals were 76.8
percent and 48.0 percent, respectively. This finding suggests that low or absent steroid
receptor levels in a tumor may identify a group which is at high risk for poor
outcome.
MANAGEMENT
In 1951, Kelley reported on the use of progesterone in three patients with advanced
endometrial cancer, citing two objective responses [54]. Ten years later, the first series
of patients treated with progestins for endometrial cancer appeared. Reviews of these
early studies ofthe systematic use ofprogestins in advanced endometrial cancer report
an objective response rate of approximately one-third, usually in the well-differen-
tiated tumors [55].
In 1981, Ehrlich et al. [6], in an analysis of 24 patients with advanced or recurrent
endometrial adenocarcinoma in which progestin receptors were measured prior to
therapy, had an 80 percent objective response to progestin therapy in patients with
progestin receptor-positive tumors compared with a 6 percent response in those with
negative tumors (p < 0.001). Also, in this series, 94 percent of nonresponders had
tumors which were progestin receptor-poor. As summarized in this paper, of the 70
patients with advanced or recurrent adenocarcinoma, 94 percent of the patients with
progestin-positive tumors responded to progestin therapy, while only 11 percent of
those with progestin-negative tumors responded. This difference in response rate was
statistically significant (p < 0.001). Quinn et al. [39] in 1985 reported on 22 patients
with recurrent or advanced disease treated with medroxyprogesterone acetate; none of
the 13 patients with progestin receptor-negative tumors responded, while only two of
nine (22 percent) with progestin receptor-positive tumors responded, and both were
complete responses. Quinn et al. [39] analyzed 94 cases and found that 82 percent of
patients responding to progestin had progestin receptor-rich tumors, while only 11
percent of those with progestin receptor-poor tumors responded to progestin. In this
review it was also noted that estrogen receptor status was as good as progestin receptor
status in predicting response, with 71 percent of the patients with estrogen receptor-
rich tumors responding and only 5 percent of patients with estrogen receptor-poor
tumors.
Kauppila et al. [38], in a 1980 study of 15 patients with advanced or recurrent
endometrial cancer treated with combination chemotherapy consisting ofAdriamycin,
cyclosphosphamide, 5-fluorouracil, and vincristine, showed that the group with low
receptor values (estrogen receptor protein and progestin receptor protein below 30
fmol/mg ofprotein) had a significantly (p < 0.025) greater response rate (70 percent)
than did the patients with higher receptor content (20 percent). In this series, all
patients had previously been treated with medroxyprogesterone acetate, which lowers
the receptor protein levels, so that this observation needs to be confirmed in patients
with no prior hormonal therapy.
Tamoxifen, a non-steroidal estrogen agonist-antagonist, with predominantly antag-
onistic properties, has also been used in the treatment ofrecurrent endometrial cancer
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[56-59]. It binds to the estrogen receptor and blocks the effect ofthe estrogen receptor
complex. Swenerton [59], in a 1980 study of 12 patients with advanced endometrial
cancer, used tamoxifen and reported one out of ten evaluable patients showed a
complete response and two partial responses. The response was a function ofthe grade
ofthe tumor, with theundifferentiated tumorsunlikely torespond. Schwartz et al. [57]
showed that tamoxifen can induce the progestin receptor in endometrial cancer, thus
suggesting the use of the combination of tamoxifen with progestins; however, Carlson
et al. [58], using this combination, showed only a 33 percent total response rate, which
is not superior tothe usual response to progestin therapy alone. Danazol, a derivativeof
ethinyl testosterone, has been reported to have progestin-like effects in endometrial
adenocarcinoma [60], thus suggesting another agent which may be effective in
treatment.
SUMMARY
The identification ofsex steroid receptor proteins in endometrial cancer has led to a
rational basis for many observations concerning the response of advanced and
recurrent tumors to hormonal therapy. There are, however, several problems with the
usual biochemical assays ofthe receptor protein content of the tumor. First, there are
technicalconsiderations, e.g., thetime between obtaining the specimen and assaying it;
second, obtaining the tissue leads to contamination with non-malignant components.
Newer immunohistochemical methods with monoclonal antibodies for localization and
quantification of the sex steroid receptors may enable better correlation with the
biologic behavior by correcting for the non-malignant fragments. These methods will
need further development and acceptance. The level ofestrogen and progestin receptor
protein in the tumor inversely parallels the grade of the tumor; that is, the higher the
level ofsex steroid content, the greater the differentiation ofthe tumor. The concept of
sex steroid receptor-rich tumors leads to arbitrarily chosen cut-off levels; these may
affect which clinicopathologic features are significantly associated with the hormone
receptor status. In analyzing survival, for example, the presence of high levels of the
sex steroid receptor protein, in general, predicts a favorable survival. Increasing the
level ofsex steroid receptor content may also identify groups ofpatients whose survival
is markedly superior to the patients with lower levels. In multiregression analysis, the
receptor status of the tumor may become an independent predictor of survival,
replacing even histologic grade. By changing the cut-off levels chosen, however, the
receptor protein status may also change; it may, in fact, be that the presence of any
receptor protein in the tumor is sufficient to identify a good risk factor. On the other
hand, the group ofpatients whose tumors lack any receptor protein do poorly, and this
group may respond better to cytotoxic chemotherpy than to hormonal therapy. Thus,
the exact role of the sex steroid receptor protein in endometrial cancer as a predictor
for treatment or for survival will demand further investigations controlling for the
factors discussed and using of new immunohistochemical techniques as well as of
biochemical assays.
REFERENCES
1. Janne 0, Kauppila A, Syrjala P, Vihko R: Comparison ofcytosol estrogen and progestin receptor status
in malignant and benign tumors and tumor-like lesions of human ovary. Int J Cancer 25:175-179,
1980
2. Berqvist A, Kullander S, Thorell J: A studyofestrogen and progesterone cytosol receptor concentration348 JOSEPH T. CHAMBERS
in benign and malignant ovarian tumors treated with medroxyprogesterone acetate. Acta Obstet
Gynecol Scand (Supplement) 101:75-81, 1981
3. Hamilton TC, Davies P, Griffiths K: Androgen and oestrogen binding in cytosols of human ovarian
tumors. J Endocr 90:421-431, 1981
4. Schwartz PE, LiVolsi VA, Hildreth N, et al: Estrogen receptors in ovarian epithelial carcinoma. Obstet
Gynecol 59:229-238, 1982
5. Ford LC, Berek JS, Lagasse LD, et al: Estrogen and progesterone receptor sites in malignancies ofthe
uterine cervix, vagina, and vulva. Gynecol Oncol 15:27-31, 1983
6. Ehrlich CE, Young PCM, Cleary RE: Cytoplasmic progesterone and estradiol receptors in normal
hyperplastic, and carcinomatous endometria: Therapeutic implications. Am J Obstet Gynecol 141:539-
546, 1981
7. Schwartz PE, MacLusky N, Sakamoto H, et al: Steroid-receptor proteins in nonepithelial malignancies
ofthe ovary. Gynecol Oncol 15:305-315, 1983
8. Schwartz PE, MacLusky N, Merino M, LiVolsi VA, Kohorn El, Eisenfeld A: Are cytosol estrogen and
progestin receptors of prognostic significance in the management of epithelial ovarian cancers? Obstet
Gynecol 68:751-758, 1986
9. Jensen EV, Smith S, DeDombre ER: Hormone dependency in breast cancer. J Steroid Biochem
7:911-917, 1976
10. Knight WA, Livingston RB, Gregory EJ, et al: Estrogen receptor as an independent prognostic factor
for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977
11. McGuire WL, Clark GM: The prognostic role ofprogesterone receptors in human breast cancer. Semin
Oncol 10(Supplement 4):2-6, 1983
12. Saez S, Chouvet C, Mayer M, et al: Estradiol and progesterone receptor as prognostic factors in human
primary breast tumors. Proceedings AACR and ASCO, San Diego, California, May 28-31, 1980.
Baltimore, MD, Waverly Press, Inc, 1980, p 139
13. Pichon MF, Pallud C, Brunet M, et al: Relationship ofpresenceofprogesterone receptors to prognosis in
early breast cancer. Cancer Res 40:3357-3360, 1980
14. Hubay CA, Pearson OH, Marshall JS, et al: Adjuvant therapy of stage II breast cancer: 48 month
follow-up ofa prospective randomized clinical trial. Breast Cancer Res Treat 1:72-82, 1981
15. Fisher B, Redmond C, Brown A, et al: Influence of tumor estrogen and progesterone receptor levels on
the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1:227-241, 1983
16. Silverberg E, Lubera JA: Cancer Statistics, 1988. CA 38(1):14, 1988
17. Christopherson WM, Alberhasky RC, Connelly PJ: Carcinoma of the endometrium. I: A clinical
pathological study ofclear cell carcinoma and secretory carcinoma. Cancer 49:1511-1523, 1982
18. Boronow RC, Morrow CP, Creasman WT, et al: Surgical staging in endometrial cancer: Clinical-
pathologic findings ofa prospective study. Obstet Gynecol 63:825-832, 1984
19. Demopoulos RI, Dubin N, NoumoffJ, et al: Prognostic significance ofsquamous differentiation in stage
I endometrial adenocarcinoma. Obstet Gynecol 68:245-250, 1986
20. Chambers SK, Kapp DS, Peschel RE, etal: Prognostic factors and sites offailure in FIGO stage I, grade
3 endometrial carcinoma. Gynecol Oncol 27:180-188, 1987
21. Chambers JT, Merino M, Kohorn El, et al: Uterine papillary serous carcinoma. Obstet Gynecol
69:109-113, 1987
22. Christopherson WM, Connelly PJ, Alberhasky RC: Carcinoma of the endometrium: an analysis of
prognosticators in patients with favorable subtypes and stage I disease. Cancer 51:1705-1709, 1983
23. Chambers JT, MacLusky N, Eisenfield A, et al: Estrogen and progestin receptor levels as prognostica-
tors for survival in endometrial cancer. Gynecol Oncol, in press
24. Geisinger KR, Homesley HD, Morgan TM, et al: Endometrial adenocarcinoma: A multiparameter
clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer
58:1518-1525, 1986
25. Creasman WT, Soper JT, Kenneth S, et al: Influence of cytoplasmic steroid receptor content on
prognosis ofearly stage endometrial carcinoma. Am J Obstet Gynecol 151:922-932, 1985
26. Liao BS, Twiggs LB, Leung BS, et al: Cytoplasmic estrogen and progesterone receptors as prognostic
parameters in primary endometrial carcinoma. Obstet Gynecol 67:463-467, 1986
27. Vihko R, Isotalo H, Kauppila A: Female sex steroid receptors in gynecological malignancies: Clinical
correlates. J Steroid Biochem 19:827-832, 1983
28. Quinn MA, Pearce P, Fortune DW, et al: Correlation between cytoplasmic steroid receptors and tumour
differentiation and invasion in endometrial carcinoma. Brit J Obstet Gynecol 92:399-406, 1985HORMONE RECEPTORS AND ENDOMETRIAL CANCER 349
29. Kauppila A, Kujansuu E, Vihko R: Cytosol estrogen and progestin receptors in endometrial carcinoma
ofpatients treated with surgery, radiotherapy, and progestin. Clinical correlates. Cancer 50:2157-2162,
1982
30. Utaaker E, Iversen OE, Skaarland E: The distribution and prognostic implications ofsteroid receptors
in endometrial carcinomas. Gynecol Oncol 28:89-100, 1987
31. Mortel R, Zaino R, Satyaswaroop PG: Heterogeneity and progesterone-receptor distribution in
endometrial adenocarcinoma. Cancer 53:113-116, 1984
32. Hunter RE, Longcope C, Jordan VC: Steroid hormone receptors in adenocarcinoma of the endome-
trium. Gynecol Oncol 10:152-161, 1980
33. Pollow K, Schmidt-Gollwitzer M, Pollow B: Progesterone- and estradiol-binding protein from normal
human endometrium and endometrial carcinoma: A comparative study. In Steroid Receptors and
Hormone-Dependent Neoplasia. Edited by JL Wittliff, 0 Dapunt. New York, Masson Publishing USA
Inc, 1980, pp 69-94
34. Martin PM, Rolland RH, Gammere M, et al: Estradiol and progesterone receptors in normal and
neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical
responses under progestin therapy, MVJ. Cancer 23:321-329, 1979
35. McCarty KS, Barton TK, Fetter BF, et al: Correlation of estrogen and progesterone receptors with
histological differentiation in endometrial adenocarcinoma. Amer J Pathol 96:171-182, 1979
36. Creasman WT, McCarty KS Sr, Barton TK, McCarty KS Jr: Clinical correlates of estrogen and
progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 55:363-370,
1980
37. Mantin JD, Hahnel R, McCartney AJ: Theeffect ofestrogen receptor status on surviVal in patients with
endometrial cancer. Am J Obstet Gynecol 147:322-324, 1983
38. Kauppila A, Janne 0, Kujansuu E, et al: Treatment of advanced endometrial adenocarcinoma with a
combined cytotoxic therapy: Predictive value ofcytosol estrogen and progestin receptor levels. Cancer
46:2162-2167, 1980
39. Quinn MA, Cauchi M, Fortune D: Endometrial carcinoma: Steroid receptors and response to
medroxyprogesterone acetate. Gynecol Oncol 21:314-319, 1985
40. Benraad THJ, Friberg LG, Koenders AJM, Kullander I: Do estrogen and progesterone receptors in
metastasizing endometrial cancers, predict the response to gestagen therapy? Acta Obstet Gynecol
Scand 59:155-159, 1980
41. Milewich L: Steroid hormone receptors in gynecologic and mammary neoplasms. In Gynecology and
Obstetrics, Volume 4(33). Edited by HJ Buchsbaum, JJ Sciarra. Hagerstown, MD, Harper and Row,
Inc Publishers, 1987, pp 3-4
42. Mortel R, Zaino R, Satyaswaroop PG: Sex Steroid Receptors and Hormonal Treatment ofEndometrial
Cancer. In Chemotherapy of Gynecologic Cancer. Edited by G Deppe. New York, Alan R. Liss, Inc
Publishers, 1984, pp 125-138
43. Gorski J, Welshons WV, Sakai D, et al: Evolution of a model of estrogen action. Recent Progress in
Hormone Research 42:297-329, 1986
44. Kelley RM, Baker WH: The role of progesterone in endometrial cancer. Cancer Res 25:1190-1196,
1965
45. Tsibris JCM, Fort FL, Cazeravec CR, et al: The uneven distribution of estrogen and progesterone
receptors in human endometrium. J Steroid Biochem 14:997-1003, 1981
46. Soper JT, McCarty KS Jr, Creasman WT, McCarty KS Sr: Histologic control of biochemical steroid
receptor analysis in endometrial carcinomas. Am J Obstet Gynecol 153:520-523, 1985
47. Soper JT, Cox EB, Budwit-Novotny D, et al: Histologic composition of endometrial carcinomas
analyzed for steroid receptor content. Am J Obstet Gynecol 157:26-27, 1987
48. Chamness GC, Mercer WD, McGuire WL: Are histochemical methods for estrogen receptors valid? J
Histochem Cytochem 28:792-798, 1980
49. McCarty KS Jr, Woodard BH, Nichols DE, et al: Comparison of biochemical and histochemical
techniques for estrogen receptor analyses in mammary carcinoma. Cancer 46:2842-2845, 1980
50. Mutch DG, Soper JT, Budwit-Novotny DA, et al: Endometrial adenocarcinoma estrogen receptor
content: Association of clinicopathologic features with immunohistochemical analysis compared with
standard biochemical methods. Am J Obstet Gynecol 157:924-931, 1987
51. Greene GL, Fitch FW, Jensen EV: Monoclonal antibodies to estrophilin: Probes for the study of
estrogen receptors. Proc Natl Acad Sci USA 77:157-161, 1980350 JOSEPH T. CHAMBERS
52. Perrot-Applanat M, Logeat F, Groyer-Picard MT, Milgrom E: Immunocytochemical study of
mammalian progesterone receptor using monoclonal antibodies. Endocrinology 116:1473-1484, 1985
53. Warembourg M, Logeat F, Milgrom E: Immunocytochemical localization of progesterone receptor in
the guinea-pig central nervous system. Brain Res 384:121-131, 1986
54. Kelley RM: In Proceeding of the Second Conference in Steroids and Cancer. Chicago, American
Medical Associates, 1951, p 116
55. Kohorn El: Hormonal and nonhormonal chemotherapy of endometrial carcinoma. In Gynecology and
Obstetrics, Volume 4, Section 20. Edited by HJ Buchsbaum, JJ Sciarra. Philadelphia, JB Lippincott
Company, 1988, pp 1-20
56. Mortel R, Levy C, Wolff JP, et al: Female sex steroid receptors in postmenopausal endometrial
carcinoma and biochemical response to an antiestrogen. Cancer Res 41:1140-1147, 1981
57. Schwartz PE, MacLusky N, Naftolin F, et al: Tamoxifen-induced increase in cytosol progestin receptor
levels in a case of metastatic endometrial cancer. Gynecol Oncol 16:41-48, 1983
58. Carlson JA Jr, Allegra JC, Day TG Jr, et al: Tamoxifen and endometrial carcinoma: Alterations in
estrogen and progesterone receptors in untreated patients and combination hormonal therapy in
advanced neoplasia. Am J Obstet Gynecol 149:149-153, 1984
59. Swenerton KD: Treatmentofadvanced endometrialadenocarcinoma with tamoxifen. CancerTreat Rep
64:805-811, 1980
60. Kauppila A, Isotalo H, Kivinen S, et al: Short-term effects ofdanazol and medroxyprogesterone acetate
on cytosol and nuclear estrogen and progestin receptors, 17 beta-hydroxysteroid dehydrogenaseactivity,
histopathology, and ultrastructure ofhuman endometrial adenocarcinoma. Int J Cancer 35(2):157-163,
1985